Hand-foot syndrome with tyrosine kinase inhibitor therapy: Treatment recommendations;Hand-Fuß-Syndrom bei Tyrosinkinaseinhibitortherapie: Empfehlungen für die Praxis

Urologe - Ausgabe A

Volumn 52, Issue 11, 2013, Pages 1574-1578

  Burbach, G J ^a   Zuberbier, T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Axitinib; Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER PATIENT; CHEMOPROPHYLAXIS; DISEASE SEVERITY; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; OUTPATIENT; QUALITY OF LIFE; STANDARDIZATION; DRUG ANTAGONISM; GERMANY; PRACTICE GUIDELINE;

ANTINEOPLASTIC AGENTS; GERMANY; HAND-FOOT SYNDROME; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84888639145     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-013-3204-7     Document Type: Article

References (21)

1. Chu D, Lacouture ME, Fillos T, Wu S (2008) Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 47:176-186
2. Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7:11-19
3. Fischer A, Wu S, Ho AL, Lacouture ME (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 30(4):1773-1781
4. Balagula Y, Wu S, Su X et al (2012) The risk of hand-foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 30:1773-1781
5. Wood LS, Lemont H, Jatoi A et al (2010) Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol 7:23-29
6. Zuehlke RL (1974) Erythematous eruption of the pamls and soles associated with mitotane therapy. Dermatologica 148:90-92
7. Baack BR, Burgdorf WH (1991) Chemotherapy-induced acral erythema. J Am Acad Dermatol 24:457-461
8. Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy-classification and management. J Dtsch Dermatol Ges 8:652-661
9. Lacouture ME, Wu S, Robert C et al (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-1011
10. Martschick A, Sehouli J, Patzelt A et al (2009) The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 29:2307-2314
11. Kollmannsberger C, Bjarnason G, Burnett P et al (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 16:543-553
12. Wollenberg A, Staehler M, Eames T (2010) Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib. Hautarzt 61:662-553
13. Lopez AM, Wallace L, Dorr RT et al (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodystesthesia. Cancer Chemother Pharmacol 44:303-306
14. Robert C, Mateus C, Spatz A et al (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299-305
15. Strumberg D, Awada A, Hirte H et al (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 42:548-556
16. Donskov F, Michaelson MD, Puzanov I et al (2012) Comparative assessment of Sunitinib-associated adverse events as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC). European Society for Medical Oncology, Vienna
17. Huptas L, Rompoti N, Herbig S et al (2011) Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel. Hautarzt 62:280-286
18. Kara IO, Sahin B, Erkisi M (2006) Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 15:414-424
19. Podlekareva Farr K, Safwat A (2011) Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 4:229-235
20. Mangili G, Petrone M, Gentile C et al (2008) Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 108:332-335
21. Kingsley EC (1994) 5-fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 120:813